Advertisement

Ranibizumab for persistent diabetic macular edema after bevacizumab treatment

Abstract

Purpose

To evaluate the efficacy of switching from bevacizumab to ranibizumab in patients with diabetic macular edema (DME).

Methods

This was a retrospective study of patients with DME initially treated with bevacizumab and switched to ranibizumab. Visual acuity (VA) and central retinal thickness (CRT) were retrieved at fixed timepoints prior to and after the switch.

Results

Forty eyes of 32 patients were included in the study. The difference in VA between any of these fixed timepoints was not statistically significant. A significant gain in VA was found in eyes that lost more than 0.1 logMAR during treatment with the last 3 bevacizumab injections. The mean CRT was significantly lower after the first 3 ranibizumab injections and at the final follow-up (p<0.001), a 67 ± 14 μm and 78 ± 18 μm reduction in thickness, respectively.

Conclusions

Switching to ranibizumab resulted in a significant decrease in the CRT of eyes with DME, and should be considered when there is a lack of response or deterioration while on bevacizumab injections. A significant gain in VA was observed in a subgroup of eyes that lost more than one line while receiving the last 3 bevacizumab injections prior to the switch.

Eur J Ophthalmol 2017; 27(2): 210 - 214

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/ejo.5000838

Authors

Gabriel Katz, Elad Moisseiev, Dafna Goldenberg, Joseph Moisseiev, Yosef Lomnicky, Yitzchak Abend, Giora Treister, Hani Levkovitch-Verbin

Article History

Disclosures

Financial support: No financial support was received for this submission.
Conflict of interest: None of the authors has conflict of interest with this submission.
Meeting presentation: Presented at the ASRS annual meeting, Vienna, July 11-14, 2015.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  •  Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan; affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv - Israel
  •  Assuta Medical Centers, Tel Aviv - Israel
  •  Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv; affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv - Israel
  •  Maccabi Healthcare Services - Israel

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.